News

On 1st November 2023, PTC Therapeutics International Limited, granted exclusive distribution rights to AxxessBio in several countries in Southeast Asia for Translarna™ (ataluren) and a service agreement for Upstaza™ (eladocagene exuparvovec). Translarna™ is indicated for the treatment of Duchenne muscular dystrophy (DMD), resulting from a nonsense mutation in the dystrophin

AxxessBio is pleased to share that GENCEBOK® (caffeine citrate) 10 MG/ML SOLUTION FOR INFUSION has been approved by the Health Sciences Authority (HSA) Singapore for apnoea of prematurity. GENCEBOK® is the first caffeine citrate approved in Singapore for above indication. GENCEBOK® was also granted the European Marketing Authorization (EMA) in

AxxessBio is pleased to announce that TEPADINA® (thiotepa) 15mg, TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 400mg multi chamber bag have been approved in Malaysia with the following indications: TEPADINA® is indicated, in combination with other chemotherapy medicinal products: – With or without total body irradiation (TBI), as conditioning treatment prior

AxxessBio is pleased to announce that TEPADINA® (thiotepa) 15mg, TEPADINA® (thiotepa) 100mg and TEPADINA® (thiotepa) 400mg multi chamber bag have been approved in Thailand with the following indications: TEPADINA® is indicated, in combination with other chemotherapy medicinal products: – With or without total body irradiation (TBI), as conditioning treatment prior